Drug information provided by: Merative, Micromedex®
Tislelizumab-jsgr injection is used to treat esophageal cancer that has spread or cannot be removed by surgery. It is given to patients who have received cancer medicines that did not contain a PD-L1 inhibitor.
Tislelizumab-jsgr is a monoclonal antibody that changes the immune system to help control the growth of cancer cells.
This medicine is to be given only by or under the direct supervision of your doctor.
Portions of this document last updated: April 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.